In the past week, ADVM stock has gone down by -1.19%, with a monthly decline of -40.27% and a quarterly plunge of -34.71%. The volatility ratio for the week is 10.79%, and the volatility levels for the last 30 days are 12.38% for Adverum Biotechnologies Inc The simple moving average for the past 20 days is -17.35% for ADVM’s stock, with a -50.44% simple moving average for the past 200 days.
Is It Worth Investing in Adverum Biotechnologies Inc (NASDAQ: ADVM) Right Now?
The 36-month beta value for ADVM is also noteworthy at 1.10. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ADVM is 13.92M, and at present, short sellers hold a 10.68% of that float. The average trading volume of ADVM on April 24, 2025 was 188.28K shares.
ADVM) stock’s latest price update
Adverum Biotechnologies Inc (NASDAQ: ADVM) has seen a rise in its stock price by 3.32 in relation to its previous close of 2.85. However, the company has experienced a -1.19% decline in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-24 that NEW YORK, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. (“Adverum” or “the Company”) (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ADVM.
Analysts’ Opinion of ADVM
Many brokerage firms have already submitted their reports for ADVM stocks, with Oppenheimer repeating the rating for ADVM by listing it as a “Outperform.” The predicted price for ADVM in the upcoming period, according to Oppenheimer is $25 based on the research report published on June 25, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ADVM reach a price target of $30. The rating they have provided for ADVM stocks is “Buy” according to the report published on April 30th, 2024.
Truist gave a rating of “Buy” to ADVM, setting the target price at $4 in the report published on July 07th of the previous year.
ADVM Trading at -29.02% from the 50-Day Moving Average
After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.73% of loss for the given period.
Volatility was left at 12.38%, however, over the last 30 days, the volatility rate increased by 10.79%, as shares sank -41.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.80% lower at present.
During the last 5 trading sessions, ADVM fell by -1.01%, which changed the moving average for the period of 200-days by -58.91% in comparison to the 20-day moving average, which settled at $3.56. In addition, Adverum Biotechnologies Inc saw -36.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADVM starting from Leonard Braden Michael, who purchase 300,000 shares at the price of $3.00 back on Apr 22 ’25. After this action, Leonard Braden Michael now owns 3,057,526 shares of Adverum Biotechnologies Inc, valued at $900,000 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Adverum Biotechnologies Inc, purchase 50,000 shares at $2.98 during a trade that took place back on Apr 23 ’25, which means that Leonard Braden Michael is holding 191,800 shares at $148,950 based on the most recent closing price.
Stock Fundamentals for ADVM
Current profitability levels for the company are sitting at:
- -150.16 for the present operating margin
- -12.49 for the gross margin
The net margin for Adverum Biotechnologies Inc stands at -130.93. The total capital return value is set at -0.96. Equity return is now at value -144.41, with -63.10 for asset returns.
Based on Adverum Biotechnologies Inc (ADVM), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01.
Currently, EBITDA for the company is -135.51 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 91.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.73.
Conclusion
In summary, Adverum Biotechnologies Inc (ADVM) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
